boosh

Boosh to Acquire Pulse Kitchen Specialty Foods Ltd.

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company") is pleased to announce that it has executed a Share Purchase Agreement dated October 1st, 2021 to purchase all the shares of Pulse Kitchen Specialty Foods Ltd. ("Pulse Kitchen").

Pulse Kitchen products 100% plant-based gluten free cheese, made from nuts, seeds, pulses and other fine ingredients. Cheese flavors include Sharp Cashew Cheddar, Almond Chevre, Dill Havarti, Almond Swiss, Vegan Pepper Jack, Cashew Kind of Blue and Smoky Cashew Cheddar. Products are sold in approximately 250 grocery stores in Canada including Whole Foods, Healthy Planet, Nature's Fare, IGA, Fresh St Market, Choices, Urban Fare, and Nesters. The production facility is located in Penticton BC and was established in 2016.


"I think joining the Boosh family is a perfect fit for us. They strive to differentiate themselves in the plant-based sector, as do we. Our emphasis at Pulse Kitchen is to create deliciously flavoured plant-based cheeses with a focus on high quality and texture allowing us to enhance our consistency relating to balancing the levels of acidity and quality, resulting in a unique set of characteristics in terms of flavour, taste and texture," states Chef Stephanos Liapis, owner and founder of Pulse Kitchen. "Our products certainly take center stage on any charcuterie board and are equally enjoyed while snacking or adding to other dishes."

"We are thrilled to welcome Stephanos, Brigitte and their team to Boosh. Not only are they amazing people, and produce amazing cheese, but their products pair beautifully with our line of Vege pate and dips from our recently acquired business, Salt Spring Harvest. Going forward Boosh will have an entire line of foods that pair naturally with wine, which happens to be a passion of mine. Having an earlier career in the food and beverage industry and owning a wine store and two wine bars, this is of special interest to me," stated founder and president, Connie Marples. She continues, "To top it off, Penticton is my hometown where I spent most of my childhood. Having a production facility where a piece of my heart is and the heart of the wine country adds to the cache of the Pulse Kitchen brand."

CEO Jim Pakulis states, "This is our third acquisition in less than nine months. As we continue to execute on our business plan including our four-prong revenue stream model; organic growth, acquisition, US expansion and E-commerce, we continue to be in discussions with other plant-based acquisition candidates who are looking for access to capital and a corporate infrastructure designed for growth."

The aggregate purchase price for Pulse Kitchen is $300,000 in cash and the issuance of 50,000 common shares, payable as follows. $100,000 payable on the closing date, minus $10,000 deposit, 50,000 common shares of Boosh issued on the Closing Date, $100,000 payable six months from the date of closing and $100,000 twelve months from closing date.

On behalf of the Board of Directors

James Pakulis
Chief Executive Officer

Telephone: (833) 882-6674

www.Booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), produces high quality, 100% plant-based gluten free, non-GMO nutritious comfort foods for the whole family. We offer six frozen meals, 3 refrigerated meals and a line of veggie pates and dips. All are sold throughout Canada with plans to start sales in the US late 2021. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward-looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's proposed use of the proceeds of its initial public offering. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward-looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99034

News Provided by Newsfile via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Need injecting into red and white cell.

How to Invest in Biotechnology (Updated 2024)

Investors interested in the life science sector are well aware of the importance of biotechnology.

From finding cures for diseases to feeding future generations, many areas of day-to-day life are influenced by players in the biotechnology space, and expert projections show the industry's future looks bright.

But how can investors gain exposure to biotechnology? Here’s a brief overview of how to invest in the expanding biotechnology market, from stocks to watch to exchange-traded funds (ETFs).

Keep reading...Show less
Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Announces 2023 Annual Meeting Results

Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona ") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in person and by proxy at the Meeting was 26,722,196, representing 10.52% of Sirona's issued and outstanding Common Shares.

All matters put forward to shareholders for consideration and approval, as set out in the Company's Management Information Circular dated 22nd of February, 2024, were approved by the requisite majority of votes cast at the Meeting. These were:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×